The Food and Drug Administration (FDA) has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

A decision on tolebrutinib for treating MS is now set for Sept. 28, after the FDA granted priority review to its approval ...

Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of ...

The FDA has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

Sanofi will soon commence a Phase I/II trial with its vaccine candidate to start generating immunogenicity data.

Sanofi (NASDAQ:SNY – Get Free Report) has been assigned an average recommendation of “Buy” from the five analysts that are currently covering the stock, Marketbeat Ratings reports. Two research ...

The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price target ...

Nathan Mammen and Cole Tipton of Snell & Wilmer LLP address the question as to how AI could affect or even upend determining ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Pharmaceuticals industry for Monday, March 24, 2025. Let’s take ...

Mira Pharmaceuticals is making moves in weight loss and smoking cessation. The biotech is trying to buy Skny Pharmaceuticals ...

Discover the top gainers and losers in the S&P 500 Healthcare Index and stay updated on major news like J&J's $55B investment and Pfizer's Haleon stake exit.